New Deterrent Stimulants for ADHD

Video

What observations are being noted in the field with new agents for the treatment of ADHD?

Timothy Wilens, MD, talks about the presentation of the APSARD 2021 conference on ADAIR Pharmacokinetics and Pharmacodynamic Data. More on the presentation can be found here.

Dr Wilens is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content
From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

The Week in Review: November 13-17

November 18th 2023
Article
Treating ADHD in Children: Concerns, Controversies, Safety Measures

Treating ADHD in Children: Concerns, Controversies, Safety Measures

July 10th 2020
Podcast
What is new in research on TMS?

TMS Research Roundup: October 28

October 27th 2023
Article
ADHD in Older Adults

ADHD in Older Adults

August 15th 2016
Podcast
ADHD

Adult ADHD: A Scientifically Invalid Disorder

October 10th 2023
Article
FDA

A New Draft Guide for Developing Stimulant Use Disorder Treatments

October 9th 2023
Article
© 2023 MJH Life Sciences

All rights reserved.